EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

European Patent Office deals blow to pharma companies in dismissing their attempts to reinstate patents covering diabetes and obesity treatments | Inhibrx antibody patent upheld as Gilead subsidiary appeal is rejected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

McGuireWoods expands team with ex-Novo Nordisk GC

21 November 2024 Firm appoints Craig Bleifer as a partner in its New York office | Bleifer brings more than three decades of experience, including senior roles at Novo Nordisk and Daiichi Sankyo.

Americas

Novo Nordisk targets Canada’s largest generics maker over diabetes drug

15 October 2024 Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.

More on this story

Careers

McGuireWoods expands team with ex-Novo Nordisk GC

21 November 2024 Firm appoints Craig Bleifer as a partner in its New York office | Bleifer brings more than three decades of experience, including senior roles at Novo Nordisk and Daiichi Sankyo.

Americas

Novo Nordisk targets Canada’s largest generics maker over diabetes drug

More on this story

Careers

McGuireWoods expands team with ex-Novo Nordisk GC

21 November 2024 Firm appoints Craig Bleifer as a partner in its New York office | Bleifer brings more than three decades of experience, including senior roles at Novo Nordisk and Daiichi Sankyo.

Americas

Novo Nordisk targets Canada’s largest generics maker over diabetes drug